Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.
Website2401 Elliott Avenue
Seattle, WA, 98121
United States
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com
Investors talking about CATX also mention
What share of all stock conversation is about CATX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% +0 | 0% +0 | 0% 0 |
Of the messages about CATX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% 0 | 45% -41 | 65.5% -21.68 | 82.41% +5.22 | ||
| Bearish | 0% 0 | 55% +41 | 34.5% +21.68 | 17.59% -5.22 |
Of the messages about CATX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 80% | 36.1% | ||
| Analysts | — | 0% | 16% | 19.14% | ||
| Technical Analysis | — | 0% | 4% | 36.2% | ||
| Controversies | — | 0% | 0% | 0% | ||
| Earnings | — | 0% | 0% | 0.71% | ||
| Macro | — | 0% | 0% | 7.85% |
Of the messages about CATX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 39.13% | 77.63% | 56.98% | 58.56% | ||
| Newcomers | 60.87% | 22.37% | 43.02% | 41.44% |